Cirrhosis and End Stage Liver Disease: complications and management of conditions such as portal hypertension, ascites and encephalopathy.

 

        Cirrhosis and end-Stage Liver Disease

o       Ascites

        676. Renal failure and bacterial infection in patients with cirrhosis and ascites: relationship with the type and the resolution of the infection (updated October 29, 2006)

 

o       Encephalopathy

        711. Hepatic Encephalopathy Predicting Survival

        751. Anxiety and Depressive Symptoms in Patients with Resolving Hepatic Encephalopathy (updated October 30, 2006)

 

o       General

        216. Impact of caffeine consumption on histological activity in patients with Chronic Active Hepatitis C

        713. Loss of muscular mass is an independent factor associated with mortality in liver cirrhosis: prospective analysis of 206 patients (updated October 29, 2006)

        715. Renal dysfunction is associated with cognitive impairment in patients with liver cirrhosis (updated October 29, 2006)

        733. Quality of Care for Ambulatory Patients with Cirrhosis in an Academic Medical Center (updated October 29, 2006)

        734. Health-Related Quality of Life among Patients with Cirrhosis in the United States (updated October 30, 2006)

        741. Clinical and biochemical effect of G-CSF administration in patients with acute on chronic liver failure

        742. A late evening snack combined with α-glucosidase inhibitor administration: Effects on liver cirrhosis

        1135. Tumor ablation plus interferon therapy can reduce the risk of death for patients with hepatitis B virus or hepatitis C virus-related resectable hepatocellular carcinoma - A meta-analysis of randomized controlled trials

 

o       Portal Hypertension

        675. Cost-effectiveness of distal splenorenal shunt (DSRS) vs. transjugular intrahepatic portosystemic shunt (TIPS) (updated October 29, 2006)

        688. Thrombophilia-associated nodular regenerative hyperplasia: a new cause of non-cirrhotic portal hypertension in HIV-infected patients

        719. The effect of antiviral therapy on clinical outcome of HCV cirrhosis with portal hypertension: a prospective cohort study

        737. Hospitalization Rates for Complications of Cirrhosis and Portal Hypertension Have Increased Significantly in the USA Between 1998 and 2003

 

o       Varices

        682. Primary Prophylaxis of Variceal Hemorrhage Patient Preferences (updated October 29, 2006)

        684. Predicting patient survival in compensated cirrhotics with refractory variceal bleeding treated with distal splenorenal (DSRS) or transjugular intrahepatic portosystemic (TIPS) shunts (updated October 29, 2006)

        708. Updated long-term outcome after variceal bleeding using currently available treatments to prevent rebleeding (updated October 29, 2006)

        718. Variceal band ligation versus beta blockers for primary prevention of variceal bleeding: An updated meta-analysis (updated October 29, 2006)

        721. Platelet count as a non-invasive predictor of esophageal varices

        728. Nationwide Trends in the Incidence of Bleeding and Non-Bleeding Esophageal Varices in Hospitalized Patients in the United States (updated October 29, 2006)

        739. Primary prophylaxis with band ligation is safe and effective in patients with contraindications, intolerance or non responding to beta-blockers: a pragmatic study

        753. Clinical Features of Upper Gastrointestinal Bleeding in Patients with Cirrhosis: A Multicenter Cohort Study